Epigenetics in human disease and prospects for epigenetic therapy

[1]  U. Bunz.  How Are Alkynes Scrambled? , 2005, Science.

[2]  F. Šorm,et al.  5-Azacytidine, a new, highly effective cancerostatic , 1964, Experientia.

[3]  M. Oshimura,et al.  Silencing of imprinted CDKN1C gene expression is associated with loss of CpG and histone H3 lysine 9 methylation at DMR-LIT1 in esophageal cancer , 2004, Oncogene.

[4]  Jorge Cortes,et al.  Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. , 2004, Blood.

[5]  Anthony P. Goldstone,et al.  Prader-Willi syndrome: advances in genetics, pathophysiology and treatment , 2004, Trends in Endocrinology & Metabolism.

[6]  C. Allis,et al.  Linking the epigenetic ‘language’ of covalent histone modifications to cancer , 2004, British Journal of Cancer.

[7]  Stuart H. Orkin,et al.  The SWI/SNF complex — chromatin and cancer , 2004, Nature Reviews Cancer.

[8]  A. Feinberg,et al.  The history of cancer epigenetics , 2004, Nature Reviews Cancer.

[9]  David I. K. Martin,et al.  Germline epimutation of MLH1 in individuals with multiple cancers , 2004, Nature Genetics.

[10]  R. Hoffman,et al.  Effects of 5-aza-2'-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. , 2003, Blood.

[11]  Ni Ai,et al.  Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. , 2003, Cancer research.

[12]  J. Issa,et al.  Comment on "Chromosomal Instability and Tumors Promoted by DNA Hypomethylation" and "Induction of Tumors in Mice by Genomic Hypomethylation" , 2003, Science.

[13]  J. Herman,et al.  Inhibition of DNA methylation and histone deacetylation prevents murine lung cancer. , 2003, Cancer research.

[14]  Eric C. Griffith,et al.  Derepression of BDNF Transcription Involves Calcium-Dependent Phosphorylation of MeCP2 , 2003, Science.

[15]  A. Bird,et al.  MeCP2 Repression Goes Nonglobal , 2003, Science.

[16]  Daisuke Hattori,et al.  DNA Methylation-Related Chromatin Remodeling in Activity-Dependent Bdnf Gene Regulation , 2003, Science.

[17]  Shirley M. Taylor,et al.  p53-mediated repression of DNA methyltransferase 1 expression by specific DNA binding. , 2003, Cancer research.

[18]  Wolfgang Fischle,et al.  Binary switches and modification cassettes in histone biology and beyond , 2003, Nature.

[19]  M. Ehrlich.  The ICF syndrome, a DNA methyltransferase 3B deficiency and immunodeficiency disease. , 2003, Clinical immunology.

[20]  R. Claus,et al.  Epigenetic targets in hematopoietic malignancies , 2003, Oncogene.

[21]  J. Ausió,et al.  Syndromes of disordered chromatin remodeling , 2003, Clinical genetics.

[22]  C. Iacobuzio-Donahue,et al.  Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. , 2003, Cancer research.

[23]  A. Probst,et al.  Erasure of CpG methylation in Arabidopsis alters patterns of histone H3 methylation in heterochromatin , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[24]  En Li,et al.  Suv 39 h-Mediated Histone H 3 Lysine 9 Methylation Directs DNA Methylation to Major Satellite Repeats at Pericentric Heterochromatin , 2003 .

[25]  D. Higgs,et al.  Transcription of antisense RNA leading to gene silencing and methylation as a novel cause of human genetic disease , 2003, Nature Genetics.

[26]  J. Herman,et al.  Specific Inhibition of DNMT1 by Antisense Oligonucleotides Induces Re-expression of Estrogen Receptor a (ER) in ER-negative Human Breast Cancer Cell Lines , 2003, Cancer biology & therapy.

[27]  K. Bair,et al.  Psammaplins from the sponge Pseudoceratina purpurea: inhibition of both histone deacetylase and DNA methyltransferase. , 2003, The Journal of organic chemistry.

[28]  P. Laird.  Early detection: The power and the promise of DNA methylation markers , 2003, Nature Reviews Cancer.

[29]  A. Feinberg,et al.  Loss of IGF2 Imprinting: A Potential Marker of Colorectal Cancer Risk , 2003, Science.

[30]  Wei Ye,et al.  Inhibition of DNA methylation and reactivation of silenced genes by zebularine. , 2003, Journal of the National Cancer Institute.

[31]  Tony Kouzarides,et al.  The Methyl-CpG-binding Protein MeCP2 Links DNA Methylation to Histone Methylation* , 2003, The Journal of Biological Chemistry.

[32]  Xiaofeng Cao,et al.  ARGONAUTE4 Control of Locus-Specific siRNA Accumulation and DNA and Histone Methylation , 2003, Science.

[33]  J. Herman,et al.  Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene. , 2003, Cancer cell.

[34]  A. Bird,et al.  Molecular biology. MeCP2 repression goes nonglobal. , 2003, Science.

[35]  J. Bender,et al.  An Arabidopsis SET domain protein required for maintenance but not establishment of DNA methylation , 2002, The EMBO journal.

[36]  B. Oostra,et al.  The X chromosome and fragile X mental retardation , 2002, Cytogenetic and Genome Research.

[37]  F. Sato,et al.  Pharmacologic unmasking of epigenetically silenced tumor suppressor genes in esophageal squamous cell carcinoma. , 2002, Cancer cell.

[38]  S. Jacobsen,et al.  DNA methylation controls histone H3 lysine 9 methylation and heterochromatin assembly in Arabidopsis , 2002, The EMBO journal.

[39]  Peter A. Jones,et al.  Histone H3-lysine 9 methylation is associated with aberrant gene silencing in cancer cells and is rapidly reversed by 5-aza-2'-deoxycytidine. , 2002, Cancer research.

[40]  Ira M. Hall,et al.  Establishment and Maintenance of a Heterochromatin Domain , 2002, Science.

[41]  Edith Heard,et al.  Antisense RNA in imprinting: spreading silence through Air. , 2002, Trends in genetics : TIG.

[42]  V. Saha,et al.  Chromatin Modification, Leukaemia and Implications for Therapy , 2002, British journal of haematology.

[43]  Lei Zhou,et al.  Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. , 2002, Journal of molecular biology.

[44]  Ira M. Hall,et al.  Regulation of Heterochromatic Silencing and Histone H3 Lysine-9 Methylation by RNAi , 2002, Science.

[45]  Xiaofeng Cao,et al.  Interplay between Two Epigenetic Marks DNA Methylation and Histone H3 Lysine 9 Methylation , 2002, Current Biology.

[46]  David A Jones,et al.  Reactivating the expression of methylation silenced genes in human cancer , 2002, Oncogene.

[47]  B. Richardson,et al.  Role of DNA methylation in the regulation of cell function: autoimmunity, aging and cancer. , 2002, The Journal of nutrition.

[48]  M. Loda,et al.  A hereditary nonpolyposis colorectal carcinoma case associated with hypermethylation of the MLH1 gene in normal tissue and loss of heterozygosity of the unmethylated allele in the resulting microsatellite instability-high tumor. , 2002, Cancer research.

[49]  T. Jenuwein,et al.  The many faces of histone lysine methylation. , 2002, Current opinion in cell biology.

[50]  A. Beaudet,et al.  A rheostat model for a rapid and reversible form of imprinting-dependent evolution. , 2002, American journal of human genetics.

[51]  Peter A. Jones,et al.  The fundamental role of epigenetic events in cancer , 2002, Nature Reviews Genetics.

[52]  J. P. Jackson,et al.  Control of CpNpG DNA methylation by the KRYPTONITE histone H3 methyltransferase , 2002, Nature.

[53]  Daiya Takai,et al.  Comprehensive analysis of CpG islands in human chromosomes 21 and 22 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Peter A. Jones,et al.  Analysis of gene induction in human fibroblasts and bladder cancer cells exposed to the methylation inhibitor 5-aza-2'-deoxycytidine. , 2002, Cancer research.

[55]  Matty P. Weijenberg,et al.  A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer , 2002, Nature Genetics.

[56]  S. Piantadosi,et al.  Reversal of GSTP1 CpG island hypermethylation and reactivation of pi-class glutathione S-transferase (GSTP1) expression in human prostate cancer cells by treatment with procainamide. , 2001, Cancer research.

[57]  E. Selker,et al.  A histone H3 methyltransferase controls DNA methylation in Neurospora crassa , 2001, Nature.

[58]  P. Jones,et al.  Altered chromatin structure associated with methylation-induced gene silencing in cancer cells: correlation of accessibility, methylation, MeCP2 binding and acetylation. , 2001, Nucleic acids research.

[59]  M. Lübbert,et al.  Cytogenetic responses in high‐risk myelodysplastic syndrome following low‐dose treatment with the DNA methylation inhibitor 5‐aza‐2′‐deoxycytidine , 2001, British journal of haematology.

[60]  J. Herman,et al.  A gene hypermethylation profile of human cancer. , 2001, Cancer research.

[61]  D. Jones,et al.  Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2'-deoxycytidine. , 2001, Molecular pharmacology.

[62]  Matthew Tudor,et al.  Loss of genomic methylation causes p53-dependent apoptosis and epigenetic deregulation , 2001, Nature Genetics.

[63]  J. Sludden,et al.  Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. , 2000, Cancer research.

[64]  D. Higgs,et al.  Molecular-clinical spectrum of the ATR-X syndrome. , 2000, American journal of medical genetics.

[65]  W. Reik,et al.  Beckwith-Wiedemann syndrome: imprinting in clusters revisited. , 2000, The Journal of clinical investigation.

[66]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[67]  Issa Jp.  CpG-island methylation in aging and cancer. , 2000 .

[68]  A. Wolffe,et al.  DNA methylation and histone deacetylation in the control of gene expression: basic biochemistry to human development and disease. , 2000, Gene expression.

[69]  J. Issa,et al.  CpG-island methylation in aging and cancer. , 2000, Current topics in microbiology and immunology.

[70]  Luke Hughes-Davies,et al.  DNA methyltransferase Dnmt1 associates with histone deacetylase activity , 2000, Nature Genetics.

[71]  D. Haber,et al.  DNA Methyltransferases Dnmt3a and Dnmt3b Are Essential for De Novo Methylation and Mammalian Development , 1999, Cell.

[72]  H. Zoghbi,et al.  Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2 , 1999, Nature Genetics.

[73]  Hengyi Xiao,et al.  Both Sp1 and Sp3 are responsible for p21waf1 promoter activity induced by histone deacetylase inhibitor in NIH3T3 cells , 1999, Journal of cellular biochemistry.

[74]  Peter A. Jones,et al.  Cancer-epigenetics comes of age , 1999, Nature Genetics.

[75]  J. Herman,et al.  Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer , 1999, Nature Genetics.

[76]  Colin A. Johnson,et al.  Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex , 1998, Nature.

[77]  S. Saitoh,et al.  Imprinting in Prader-Willi and Angelman syndromes. , 1998, Trends in genetics : TIG.

[78]  R. Jaenisch,et al.  RNA and the Epigenetic Regulation of X Chromosome Inactivation , 1998, Cell.

[79]  S. Minucci,et al.  Fusion proteins of the retinoic acid receptor-α recruit histone deacetylase in promyelocytic leukaemia , 1998, Nature.

[80]  C. Walsh,et al.  Cytosine methylation and the ecology of intragenomic parasites. , 1997, Trends in genetics : TIG.

[81]  R. Jaenisch,et al.  Mutagenicity of 5-aza-2'-deoxycytidine is mediated by the mammalian DNA methyltransferase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[82]  M. Loda,et al.  Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines. , 1997, Cancer research.

[83]  R. Weinberg,et al.  Suppression of intestinal neoplasia by DNA hypomethylation , 1995, Cell.

[84]  R. Jaenisch,et al.  Toxicity of 5-aza-2'-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[85]  M. Herlyn,et al.  Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2'-deoxycytidine. , 1994, Cancer research.

[86]  M. Surani,et al.  Activation of an imprinted Igf 2 gene in mouse somatic cell cultures , 1993, Molecular and cellular biology.

[87]  A. Riggs,et al.  Carcinogenicity and haemoglobin synthesis induction by cytidine analogues. , 1988, British Journal of Cancer.

[88]  P. Jones,et al.  Differential nuclear protein binding to 5-azacytosine-containing DNA as a potential mechanism for 5-aza-2'-deoxycytidine resistance , 1987, Molecular and cellular biology.

[89]  M. Whitters,et al.  Activation of a chicken embryonic globin gene in adult erythroid cells by 5-azacytidine and sodium butyrate. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[90]  V. L. Wilson,et al.  DNA methylation decreases in aging but not in immortal cells. , 1983, Science.

[91]  R. Henneberry,et al.  beta-Adrenergic receptor induction in HeLa cells: synergistic effect of 5-azacytidine and butyrate. , 1982, Biochemical and biophysical research communications.

[92]  B. Migeon,et al.  Studies of X chromosome DNA methylation in normal human cells , 1982, Nature.

[93]  T. Mohandas,et al.  Reactivation of an inactive human X chromosome: evidence for X inactivation by DNA methylation. , 1981, Science.

[94]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.

[95]  P. Jones,et al.  Functional striated muscle cells from non-myoblast precursors following 5-azacytidine treatment , 1977, Nature.

[96]  R Holliday,et al.  DNA modification mechanisms and gene activity during development , 1975, Science.

[97]  Arthur D. Riggs,et al.  X inactivation, differentiation, and DNA methylation. , 1975, Cytogenetics and cell genetics.